GLP-1 medications work by mimicking a natural hormone that reduces hunger, slows stomach emptying, and improves insulin secretion
doi:10.3390/molecules23020509
Most of these improvements come from weight loss, but studies suggest semaglutide may also directly affect how your body processes fats
Lilly submitted the diabetes NDA in October 2021, the FDA approved Mounjaro in May 2022, and the obesity approval (Zepbound) followed in November 2023
Active device-based approaches, including microneedle patches, jet injectors, and ultrasound-enhanced delivery systems, are expanding the range of peptides amenable to this route (
Hims CEO Andrew Dudum takes a GLP-1 microdose, he told Bloomberg earlier this year